Recent advancement in drugs of Alzheimer's disease
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20223367Keywords:
Alzheimer disease, Neuro-degeneration, Tau-protein, β-amyloid protein, Presymptomatic, Clinical trialsAbstract
Alzheimer's disease (AD), a multifaceted neurological ailment that progresses over time, is the most common cause of dementia in older people. Intracellular neurofibrillary tangles and extracellular amyloidal protein deposits contribute to senile plaques on a pathological level. AD symptoms vary depending on the stage of the disease. Depending on the severity of cognitive impairment, AD is classified as preclinical or presymptomatic, mild, or dementia-stage. In addition, the condition is influenced by a number of risk factors, including advancing age, hereditary factors, head injuries, vascular diseases, infections, and environmental variables. There are currently only two types of licenced medications to treat AD: inhibitors of the cholinesterase enzyme such as donepezil, rivastigmine, galantamine and antagonists of N-methyl d-aspartate (NMDA) such as memantine, both of which are only effective in treating the symptoms of the disease and do not cure or prevent it.
Metrics
References
Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules. 2020;25(24):5789.
Alzheimer’s Association. 2015 Alzheimer's disease facts and figures. Alzheimers Dement. 2015;11(3):332-84.
Andreson P. Psychiatric Disorders Linked to Earlier Alzheimer's Onset. Medscape, 2021. Available at: https:// www.medscape.com/ view article /946495. Accessed on 02 November 2022.
Andreson P. Higher Rate of Alzheimer's in Women Explained. Medscape, 2020, Available at: https://www.medscape.com/viewarticle/93. Accessed on 02 November 2022.
WHO. Fact sheet: dementia, 2022. Available at: https://www.who.int/newsroom/factsentia. Accessed on 02 November 2022.
Armstrong R. Risk factors for Alzheimer's disease. Folia Neuropathol. 2019;57(2):87-105.
National Institute on Aging. Fact sheet: Alzheimer’s disease, 2021. Available at: https://www.nia.nih.gov/health/alzheimers-fact-sheet. Accessed on 02 November 2022.
Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, de Leon MJ. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis. 2010;20(3):843-54.
Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer's disease. Subcell Biochem. 2012;65:329-52.
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292-323.
Kumar A, Sidhu J, Goyal A. Alzheimer Disease. Treasure Island, FL: StatPearls Publishing; 2022.
Perl DP. Neuropathology of Alzheimer's disease. Mt Sinai J Med. 2010;77(1):32-42.
Armstrong RA. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer's disease. Folia Neuropathol. 2009;47(4):289-99.
Lleo A, Nunez-Llaves R, Alcolea D, Chiva C, Balateu-Panos D, Colom-Cadena M, et al. Changes in synaptic proteins precede neurodegeneration markers in preclinical ADcerebrospinal fluid. Mol Cell Proteom. MCP. 2019;18:546-60.
Seltzer B. Donepezil: a review. Expert Opin Drug Metab Toxicol. 2005;1(3):527-36.
Onor ML, Trevisiol M, Aguglia E. Rivastigmine in the treatment of Alzheimer's disease: an update. Clin Interv Aging. 2007;2(1):17-32.
17. Medscape. Fact sheet. Galantamine, 2022. Available at: https://reference.medscape.com/ ergalantamine-343059. Accessed on 02 November 2022.
Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003;18(1):S23-32.
Medscape Fact sheet. Memantine, 2022. Available at: https:// reference. medscape. com/drug/namenda-xr-memantine-343063. Accessed on 02 November 2022.
John V, Beck JP, Bienkowski MJ, Sinha S, Heinrikson RL. Human beta-secretase (BACE) and BACE inhibitors. J Med Chem. 2003;46(22):4625-30.
Wessels AM, Lines C, Stern RA, Kost J, Voss T, Mozley LH, et al. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. Alzheimers Dement. 2020;16(11):1483-92.
Biscaro B, Lindvall O, Tesco G, Ekdahl CT, Nitsch RM. Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer's disease. Neurodegener Dis. 2012;9(4):187-98.
FDA. Fact sheet- FDA Grants accelerated Approval for Alzheimer’s disease, 2021. Available at: https://www.fda.gov/news-events/pressalzheimers-drug. Accessed on 02 November 2022.
Focht M. Genetic Link Adds to Gut- Brain Axis Theory in Alzheimer’s disease, 2022. Available at: https://www.medscape.com/viewarticle/. Accessed on 02 November 2022.
Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3-14.
Pardridge WM. Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain. Front Aging Neurosci. 2020;11:373.
Pardridge WM. CSF, blood-brain barrier, and brain drug delivery. Expert Opin Drug Deliv. 2016;13(7):963-75.
Braun C, Sakamoto A, Fuchs H, Ishiguro N, Suzuki S, Cui Y, et al. Quantification of Transporter and Receptor Proteins in Dog Brain Capillaries and Choroid Plexus: Relevance for the Distribution in Brain and CSF of Selected BCRP and P-gp Substrates. Mol Pharm. 2017;14(10):3436-47.
Boswell CA, Mundo EE, Ulufatu S, Bumbaca D, Cahaya HS, Majidy N, et al. Comparative physiology of mice and rats: radiometric measurement of vascular parameters in rodent tissues. Mol Pharm. 2014;11(5):1591-8.
Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016;537(7618):50-6.
Wang S, Mustafa M, Yuede CM, Salazar SV, Kong P, Long H, et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an AD model. J Exp Med. 2020;217.
Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367-85.
Pardridge WM. Alzheimer's disease: future drug development and the blood-brain barrier. Expert Opin Investig Drugs. 2019;28(7):569-72.
Sheikov N, McDannold N, Vykhodtseva N, Jolesz F, Hynynen K. Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med Biol. 2004;30(7):979-89.
Zhao B, Chen Y, Liu J, Zhang L, Wang J, Yang Y, et al. Blood-brain barrier disruption induced by diagnostic ultrasound combined with microbubbles in mice. Oncotarget. 2017;9(4):4897-914.
Sun A, Benet LZ. Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis. Pharmacology. 2020;105(3-4):145-63.
Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235-49.
Pardridge WM. Treatment of Alzheimer's Disease and Blood-Brain Barrier Drug Delivery. Pharmaceuticals (Basel). 2020;13(11):394.
Cano A, Turowski P, Ettcheto M, Duskey JT, Tosi G, Sánchez-López E, et al. Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges. J Nanobiotechnology. 2021;19(1):122.
Inuzuka H, Liu J, Wei W, Rezaeian AH. PROTACs technology for treatment of Alzheimer's disease: Advances and perspectives. Acta Mater Med. 2022;1(1):24-41.
Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2019. Alzheimers Dement (N Y). 2019;5:272-93.
Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. J Neurol Neurosurg Psychiatry. 2016;87(9):993-9.
Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020;27(1):18.
Downloads
Published
How to Cite
Issue
Section
